Lamivudine/tenofovir

Lamivudine/tenofovir disoproxil, sold under the brand name Cimduo among others, is a fixed-dose combination drug for the treatment of HIV/AIDS in adults and children weighing more than 35 kg.[1] It contains lamivudine and tenofovir disoproxil.[1] In the United States, it was approved by the Food and Drug Administration (FDA) in February 2018, for the treatment of HIV-1 infection.[1][2] It is taken by mouth.[1]

Lamivudine/tenofovir
Combination of
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleotide reverse transcriptase inhibitor
Clinical data
Trade namesCimduo, Temixys
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa618039
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

References
  1. "Cimduo- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 22 March 2018. Retrieved 26 March 2020.
  2. "Drug Approval Package: Cimduo (lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 27 November 2018. Retrieved 26 March 2020.

Further reading


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.